Corcept Therapeutics Incorporated (CORT) Guidance & Earnings Results
On 2026-07-29 Corcept Therapeutics Incorporated raised guidance: "Revenue guidance raised to $1.1-$1.2 billion from prior (not…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CORTCorcept Therapeutics IncorporatedFollow CORT — free
—
Price chart with a free account
- Market cap
- 9.3B
- P/E TTM
- 204.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Raised | Revenue guidance raised to $1.1-$1.2 billion from prior (not specified). · full year |
| 30 Apr 26 | Raised | Revenue guidance raised to $950-$1,050 million · full year |
| 24 Feb 26 | Raised | 2026 revenue guidance $900M-$1,000M vs 2025 actual $761.4M |
| 4 Nov 25 | Lowered | FY2025 revenue guidance $800-850M (prior not stated but implied lower) · full year |
| 31 Jul 25 | Raised | FY2025 revenue raised to $850-900M from prior range (not stated but implied higher) · full year |
Corcept Therapeutics Incorporated — questions
- What guidance did Corcept Therapeutics Incorporated give?
- On 2026-07-29: "Revenue guidance raised to $1.1-$1.2 billion from prior (not specified)."
- When does Corcept Therapeutics Incorporated report earnings?
- Corcept Therapeutics Incorporated's next earnings report is expected on 2026-11-04.
Every figure on this page comes from Corcept Therapeutics Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.